Quantcast

Latest treatment of bipolar disorder Stories

2014-05-12 08:28:11

BOSTON, May 12, 2014 /PRNewswire/ -- Verde Media Group Inc. (OTC:VMGI) and its Biotech Division ("VMBD") announces that Butazyme, LLC, "BTZ" a wholly owned company of VMBD, has broken ground and commenced construction of the omega-3 project site in Asia. The joint venture with Phoenix Energy "PXE" is fully financed and involves scaling and co-developing the BTZ omega-3 technology to 20,000 liters in phase-I. BTZ has developed a proprietary microbial technology to produce high value...

2014-05-07 23:11:26

Dr. Robert Moss discusses the Clinical Biopsychology Model as a brain-based psychotherapy approach from its origin to its current status. It represents a major step toward true psychotherapy integration. Greenville, SC (PRWEB) May 07, 2014 Clinical neuropsychologist Robert A. Moss, Ph.D., FACPN, FAACP discussed the origin and current status of his work on the columnar brain code model (Dimensional Systems Model) and its applied treatment approach (Clinical Biopsychology). He has discussed...

2014-05-07 12:30:30

WOODBRIDGE, ON, May 7, 2014 /PRNewswire/ - Pivotal Therapeutics Inc. (OTCQX: PVTTF) (CSE: PVO), a specialty pharmaceutical company with a focus on Omega-3 therapies for cardiovascular disease (CVD) and overall health, announced today that the U.S. Patent and Trademark Office (USPTO) has issued Patent Number 8,715,648 titled "Formulations Comprising Omega-3 Fatty Acids and Anti-Obesity Agent for the Reduction of Body Weight in Cardiovascular Disease Patients (CVD) and Diabetics"....

2014-05-06 16:32:06

Companion health economics analysis shows Transcranial Magnetic Stimulation (TMS) is cost-effective among patients who fail to benefit from prior antidepressant medication NEW YORK, May 6, 2014 /PRNewswire/ -- Neuronetics, Inc. announced today a new analysis of data at the annual meeting of the American Psychiatric Association that shows Transcranial Magnetic Stimulation (TMS) administered with the NeuroStar TMS Therapy System resulted in greater symptom improvement than next-choice...

2014-05-06 16:31:55

WOODBRIDGE, ON, May 6, 2014 /PRNewswire/ - Pivotal Therapeutics Inc. (OTCQX: PVTTF) (CSE: PVO), a specialty pharmaceutical company with a focus on Omega-3 therapies for cardiovascular disease (CVD) and overall health, is pleased to announce that it presented two posters at the American Heart Association's Arteriosclerosis, Thrombosis and Vascular Biology (ATVB) 2014 Scientific Sessions held in Toronto, Ontario, Canada, May 1-3, 2014. Both posters discussed Omega-3 deficiency (OM3D)...

2014-05-06 14:42:47

Pilot study reveals a majority of medication-free patients treated with NeuroStar TMS experienced remission after 6 weeks with durable effects through 3 months Neuronetics, Inc. announced today results from a new, dual-arm randomized pilot study that showed a trend toward symptomatic improvements with once-monthly TMS maintenance therapy in medication-free patients treated with NeuroStar TMS Therapy® for Major Depressive Disorder (MDD). Six weeks of acute NeuroStar TMS Therapy induced...

2014-05-05 16:26:47

Pilot Study Reveals a Majority of Medication-Free Patients Treated with NeuroStar TMS Experienced Remission After Six Weeks with Durable Effects Through Three Months NEW YORK, May 5, 2014 /PRNewswire/ -- Neuronetics, Inc. announced today results from a new, dual-arm randomized pilot study that showed a trend toward symptomatic improvements with once-monthly TMS maintenance therapy in medication-free patients treated with NeuroStar TMS Therapy(®) for Major Depressive Disorder (MDD)....

2014-05-01 16:31:22

WOODBRIDGE, ON, May 1, 2014 /PRNewswire/ - Pivotal Therapeutics Inc. (OTCQX: PVTTF) (CSE: PVO), a specialty pharmaceutical company with a focus on Omega-3 therapies for cardiovascular disease (CVD) and overall health, is pleased to announce that it will be presenting two posters at the American Heart Association's Arteriosclerosis, Thrombosis and Vascular Biology (ATVB) 2014 Scientific Sessions in Toronto, Ontario, Canada, May 1-3, 2014. The first poster entitled "Correlation...

2014-05-01 16:31:16

WOODBRIDGE, ON, May 1, 2014 /PRNewswire/ - Pivotal Therapeutics Inc. (OTCQX: PVTTF) (CSE: PVO), a specialty pharmaceutical company with a focus on Omega-3 therapies for cardiovascular disease (CVD) and overall health, announces a correction to its press release issued yesterday entitled "Pivotal Therapeutics Announces 2013 Financial Results". The decrease in the loss from 2012 to 2013 of $745,342 was inadvertently overstated by $91,520. The correct decrease in loss is $653,822 and...

2014-04-30 20:24:05

WOODBRIDGE, ON, April 30, 2014 /PRNewswire/ - Pivotal Therapeutics Inc. (OTCQX: PVTTF) (CSE: PVO), a specialty pharmaceutical company with a focus on Omega-3 therapies for cardiovascular disease (CVD) and overall health, announced its operational highlights and financial results for the fiscal year ended December 31, 2013. All dollar amounts referenced herein are in Canadian dollars unless otherwise stated. Financial Review Sales for the year ended 2013 totaled $303,530 versus...


Word of the Day
caparison
  • A cloth or covering, more or less ornamented, laid over the saddle or furniture of a horse, especially of a sumpter-horse or horse of state.
  • Clothing, especially sumptuous clothing; equipment; outfit.
  • To cover with a caparison, as a horse.
  • To dress sumptuously; adorn with rich dress.
This word ultimately comes from the Medieval Latin 'cappa,' cloak.
Related